Case Report
Methotrexate-Associated Lymphoproliferative Disorder Developed Ectopically in the Maxillary Gingiva and Bilateral Lungs
Table 1
Clinical findings of 51 cases of MTX-LPD in the oral cavity and 84 in the whole body.
| | Oral cavity | Whole body |
| | No. of cases | 51 | 84 | | Age | | | | Median (range) | 70.2 (40–87) | 67.6 (34–87) | | Sex | | | | Male | 14 (27.5%) | 24 (28.6%) | | Female | 37 (72.5%) | 60 (71.4%) | | MTX administration | | 2.5 | | Dose (mg/week), median (range) | 7.26 (2.0–15.5) | 5.84 (4.0–8.0) | | Duration (month), median (range) | 99.0 (1–360) | 56.7 (2–193) | | Autoimmune disease | | | | Rheumatoid arthritis | 50 (98.0%) | 36 (100%) | | Others | 1 (2.0%) | 5 (SS, SLE, PMR) | | Duration (month), median (range) | 142.8 (6–396) | 105.5 (27–360) | | Primary site | | | | Gingiva | 39 (76.5%) | | | Tongue | 6 (11.8%) | | | Mouth floor | 2 (3.9%) | | | Plate | 2 (3.9%) | | | Others | 2 (3.9%) | | | Multiple sites | | | | (+) | 11 (21.6%) | 70 (83.3%) | | Oral | 5 | | | Others (lung and liver) | 6 | | | (−) | 40 (78.4%) | 12 (14.3%) | | EBV infection | | | | (+) | 49 (96.1%) | 25 (29.8%) | | (−) | 1 (2.0%) | 51 (60.7%) | | Unknown | 1 (2.0%) | 8 (9.5%) | | Histopathological diagnosis | | | | DLBCL | 38 (74.5%) | 52 (61.9%) | | Hodgkin’s lymphoma | 6 (11.8%) | 14 (16.7%) | | Others | 7 (13.7%) | 18 (21.5%) | | Treatment | | | | W | 39 (76.5%) | 33 (39.3%) | | C | 5 (9.8%) | 41 (48.8%) | | W⟶C | 4 (7.8%) | 4 (4.8%) | | Others | 3 (5.9%) | 6 (7.1%) | | Recurrence | | | | (+) | 2 (3.9%) | 19 (22.6%) | | (−) | 40 (78.4%) | 59 (70.2%) | | Unknown | 9 (17.6%) | 6 (7.2%) |
|
|
MTX, methotrexate; SS, Sjogren's syndrome; SLE, systemic lupus erythematosus; PMR, polymyalgia rheumatica EBV, Epstein-Barr virus; DLBCL, diffuse large B-cell lymphoma; W, withdrawal of MTX; C, chemotherapy
|
